Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | P2RY12 | Q9H244 | 14/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2685700 | 0.87 | P2RY12 (0.40) | ALDH1A1KDM4EP2RY12MAPK1 | |
| SCHEMBL2685314 | 0.81 | MAPT (0.47) | LMNAP2RY12MAPK1MAPT | |
| SCHEMBL12991880 | 0.79 | P2RY12 (0.48) | CYP2C9CYP2C19ALDH1A1P2RY12MAPK1 | |
| SCHEMBL1187052 | 0.76 | CYP2C9 (0.47) | CYP2C9CYP2C19ALDH1A1LMNAP2RY12 | |
| SCHEMBL1179271 | 0.75 | P2RY12 (0.47) | CYP2C9CYP2C19ALDH1A1P2RY12MAPK1 | |
| SCHEMBL15449653 | 0.73 | CYP2C9 (0.56) | CYP2C9CYP2C19ALDH1A1KDM4EP2RY12 | |
| SCHEMBL2686396 | 0.72 | ALDH1A1 (0.54) | CYP2C9CYP2C19ALDH1A1KDM4ELMNA | |
| SCHEMBL31050105 | 0.71 | ALDH1A1 (0.61) | CYP2C9CYP2C19ALDH1A1P2RY12MAPK1 | |
| SCHEMBL337203 | 0.71 | ALDH1A1 (0.61) | CYP2C9CYP2C19ALDH1A1P2RY12MAPK1 | |
| SCHEMBL519387 | 0.70 | CYP2C9 (0.56) | CYP2C9CYP2C19ALDH1A1KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120115827-A1 | 3-AMINOBENZAMIDE COMPOUNDS AND VANILLOID RECEPTOR SUBTYPE 1 (VR1) INHIBITORS | JAPAN TOBACCO INC. (JP) | 2012-05-10 | — | — | US | disclosed |
| US-20100022523-A1 | 3-AMINOBENZAMIDE COMPOUNDS AND VANILLOID RECEPTOR SUBTYPE 1 (VR1) INHIBITORS | JAPAN TOBACCO INC. (JP) | 2010-01-28 | — | — | US | disclosed |
| EP-1775283-A1 | 3-AMINOBENAMIDE COMPOUND AND VANILLOID RECEPTOR 1 (VR1) ACTIVITY INHIBITOR | Japan Tobacco, Inc. (JP) | 2007-04-18 | — | — | EP | disclosed |
| US-20060035939-A1 | 3-Aminobenzamide compounds and inhibitors of vanilloid receptor subtype 1 (VR1) activity | JAPAN TOBACCO INC. (JP) | 2006-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022523-A1 | 3-AMINOBENZAMIDE COMPOUNDS AND VANILLOID RECEPTOR SUBTYPE 1 (VR1) INHIBITORS | TRPV1, TRPV6, HVCN1 | CYP2C9 1538/4885CYP2C19 1837/4885ALDH1A1 1417/4885 |
| US-20060035939-A1 | 3-Aminobenzamide compounds and inhibitors of vanilloid receptor subtype 1 (VR1) activity | TRPV1, TRPV6, TRPV3 | CYP2C9 1581/4885CYP2C19 1857/4885ALDH1A1 1481/4885 |
| US-20120115827-A1 | 3-AMINOBENZAMIDE COMPOUNDS AND VANILLOID RECEPTOR SUBTYPE 1 (VR1) INHIBITORS | TRPV1, TRPV6, HVCN1 | CYP2C9 2338/4885CYP2C19 2260/4885ALDH1A1 1643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.